HK1070823A1 - N3 alkylated benzimidazole derivatives as mek inhibitors - Google Patents
N3 alkylated benzimidazole derivatives as mek inhibitorsInfo
- Publication number
- HK1070823A1 HK1070823A1 HK05103569.0A HK05103569A HK1070823A1 HK 1070823 A1 HK1070823 A1 HK 1070823A1 HK 05103569 A HK05103569 A HK 05103569A HK 1070823 A1 HK1070823 A1 HK 1070823A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- benzimidazole derivatives
- mek inhibitors
- alkylated benzimidazole
- alkylated
- mek
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36400702P | 2002-03-13 | 2002-03-13 | |
PCT/US2003/007864 WO2003077914A1 (en) | 2002-03-13 | 2003-03-13 | N3 alkylated benzimidazole derivatives as mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1070823A1 true HK1070823A1 (en) | 2005-06-30 |
Family
ID=28041856
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05103569.0A HK1070823A1 (en) | 2002-03-13 | 2005-04-26 | N3 alkylated benzimidazole derivatives as mek inhibitors |
HK10105717.9A HK1141976A1 (en) | 2002-03-13 | 2010-06-09 | N3 alkylated benzimidazole derivatives as mek inhibitors |
HK11107302.5A HK1153139A1 (zh) | 2002-03-13 | 2011-07-13 | 作為 抑制劑的 烷基化苯並咪唑衍生物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10105717.9A HK1141976A1 (en) | 2002-03-13 | 2010-06-09 | N3 alkylated benzimidazole derivatives as mek inhibitors |
HK11107302.5A HK1153139A1 (zh) | 2002-03-13 | 2011-07-13 | 作為 抑制劑的 烷基化苯並咪唑衍生物 |
Country Status (35)
Country | Link |
---|---|
US (11) | US20030232869A1 (zh) |
EP (5) | EP2130537B1 (zh) |
JP (4) | JP4093966B2 (zh) |
KR (3) | KR100984573B1 (zh) |
CN (4) | CN101633645B (zh) |
AR (3) | AR038971A1 (zh) |
AT (1) | ATE449605T1 (zh) |
AU (2) | AU2003218157C1 (zh) |
BE (1) | BE2019C510I2 (zh) |
BR (1) | BR122018007328B8 (zh) |
CA (1) | CA2478374C (zh) |
CL (2) | CL2012002380A1 (zh) |
CY (3) | CY1109727T1 (zh) |
DE (1) | DE60330227D1 (zh) |
DK (4) | DK2130537T3 (zh) |
DO (4) | DOP2003000613A (zh) |
ES (5) | ES2549159T3 (zh) |
HK (3) | HK1070823A1 (zh) |
HU (2) | HUE025767T2 (zh) |
IL (4) | IL163995A0 (zh) |
IS (4) | IS2748B (zh) |
LT (1) | LTC1482932I2 (zh) |
LU (1) | LUC00100I2 (zh) |
MX (1) | MXPA04008893A (zh) |
NL (1) | NL300974I2 (zh) |
NZ (1) | NZ535158A (zh) |
PA (1) | PA8569301A1 (zh) |
PL (5) | PL233177B1 (zh) |
PT (4) | PT3000810T (zh) |
SG (3) | SG148857A1 (zh) |
SI (4) | SI2130537T1 (zh) |
TW (3) | TWI350285B (zh) |
UA (1) | UA77765C2 (zh) |
WO (1) | WO2003077914A1 (zh) |
ZA (1) | ZA200407220B (zh) |
Families Citing this family (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL163995A0 (en) * | 2002-03-13 | 2005-12-18 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
WO2004054515A2 (en) * | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
JPWO2004075915A1 (ja) * | 2003-02-26 | 2006-06-01 | 興和株式会社 | アレルギー性接触性皮膚炎治療薬 |
JP4896717B2 (ja) * | 2003-07-24 | 2012-03-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | N−メチル−置換ベンゾアミダゾール |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
JP5042626B2 (ja) | 2003-09-22 | 2012-10-03 | エス*バイオ プライベート リミティッド | ベンズイミダゾール誘導体:製造及び医薬適用 |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
KR101190912B1 (ko) * | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
KR101223914B1 (ko) * | 2003-11-21 | 2013-01-18 | 어레이 바이오파마 인크. | Akt 단백질 키나제 억제제 |
EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
PT1802579E (pt) | 2004-10-20 | 2014-02-17 | Merck Serono Sa | Derivados da 3-arilaminopiridina |
WO2006058752A1 (en) * | 2004-12-01 | 2006-06-08 | Laboratoires Serono S.A. | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
US7429667B2 (en) * | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
WO2007044084A2 (en) * | 2005-05-18 | 2007-04-19 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
BRPI0612306A2 (pt) * | 2005-06-23 | 2010-11-03 | Array Biopharma Inc | processo snar para preparar composto de benzimidazol |
KR101351190B1 (ko) * | 2005-06-23 | 2014-01-14 | 아스트라제네카 아베 | 벤즈이미다졸 화합물의 제조 방법 |
US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
CN109053523B (zh) | 2005-10-07 | 2022-03-25 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
AU2012261703B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
AU2013203939B2 (en) * | 2005-10-07 | 2015-08-13 | Exelixis, Inc. | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
US7968108B2 (en) * | 2005-10-25 | 2011-06-28 | Metbro Distributing L.P. | Hydrogen cyanamide pesticide formulations |
US7572460B2 (en) * | 2005-10-25 | 2009-08-11 | Rodrigo Rodriguez-Kabana | Hydrogen cyanamide pesticide formulations |
US20090030058A1 (en) * | 2005-12-21 | 2009-01-29 | Mohammed Pervez | Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer |
TWI405756B (zh) * | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
CA2534243A1 (fr) | 2006-01-25 | 2007-07-25 | Hydro Quebec | Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
EA016674B1 (ru) * | 2006-04-18 | 2012-06-29 | Ардеа Байосайенсиз, Инк. | Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов mek |
MY147628A (en) | 2006-07-06 | 2012-12-31 | Array Biopharma Inc | Cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
CN101511842B (zh) | 2006-07-06 | 2012-10-31 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶 |
DK2054418T3 (da) | 2006-07-06 | 2012-02-27 | Array Biopharma Inc | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
WO2008016123A1 (fr) * | 2006-08-03 | 2008-02-07 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
CN101583616B (zh) * | 2006-08-21 | 2012-05-30 | 健泰科生物技术公司 | 氮杂苯并噻吩基化合物及使用方法 |
BRPI0714635A2 (pt) * | 2006-08-21 | 2013-06-18 | Genentech Inc | compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune |
WO2008024724A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
JO2985B1 (ar) | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
WO2008125820A1 (en) * | 2007-04-13 | 2008-10-23 | Astrazeneca Ab | Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii |
US8509487B2 (en) * | 2007-04-19 | 2013-08-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for optically measuring a parameter of an object |
WO2008157179A2 (en) | 2007-06-12 | 2008-12-24 | Genentech, Inc. | N-substituted azaindoles and methods of use |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
AR067413A1 (es) | 2007-07-05 | 2009-10-07 | Genentech Inc | Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
WO2009006569A1 (en) * | 2007-07-05 | 2009-01-08 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
JP2011500657A (ja) * | 2007-10-15 | 2011-01-06 | アストラゼネカ アクチボラグ | 組合せ059 |
JP5453290B2 (ja) | 2007-11-12 | 2014-03-26 | 武田薬品工業株式会社 | Mapk/erkキナーゼ阻害剤 |
RU2498985C2 (ru) | 2007-12-19 | 2013-11-20 | Дженентек, Инк. | 8-анилиноимидазопиридины и способы их использования |
KR101195329B1 (ko) | 2007-12-19 | 2012-10-29 | 제넨테크, 인크. | 5-아닐리노이미다조피리딘 및 사용 방법 |
EP2234982A1 (en) | 2007-12-20 | 2010-10-06 | F. Hoffmann-La Roche AG | Substituted hydantoins as mek kinase inhibitors |
AU2008340247B2 (en) | 2007-12-21 | 2012-11-15 | Genentech, Inc. | Azaindolizines and methods of use |
AU2009204025B2 (en) * | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
JP5539225B2 (ja) * | 2008-01-09 | 2014-07-02 | アレイ バイオファーマ、インコーポレイテッド | Aktタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
SA109300195B1 (ar) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | تركيبة صيدلانية جديدة مضادة للسرطان |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
EP2293472A1 (en) | 2008-06-23 | 2011-03-09 | Panasonic Corporation | Wireless communication base station apparatus and reference signal allocation method |
MX2010014565A (es) * | 2008-07-01 | 2011-03-04 | Genentech Inc | Isoindolona y metodos de uso. |
RU2509078C2 (ru) | 2008-07-01 | 2014-03-10 | Дженентек, Инк. | Бициклические гетероциклы в качестве ингибиторов киназы мек |
NZ591498A (en) | 2008-08-04 | 2012-09-28 | Merck Patent Gmbh | Novel phenylamino isonicotinamide compounds |
CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资(香港)有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
EP2358202B1 (en) * | 2008-11-03 | 2016-06-15 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
US8993630B2 (en) | 2008-11-10 | 2015-03-31 | Bayer Intellectual Property Gmbh | Substituted sulphonamido phenoxybenzamides |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
CN102656142A (zh) | 2009-10-21 | 2012-09-05 | 拜耳制药股份公司 | 取代的苯磺酰胺 |
CA2777071A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
EP2491016A1 (en) | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
BR112012032884A2 (pt) | 2010-06-25 | 2016-11-08 | Novartis Ag | compostos e composições heteroarílicos como inibidores de quinase proteica |
CN103221043B (zh) | 2010-08-05 | 2016-04-06 | 卡斯西部储备大学 | 用于治疗神经元连接发育障碍的erk抑制剂 |
EA022623B1 (ru) | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
CN103282351A (zh) | 2010-10-29 | 2013-09-04 | 拜耳知识产权有限责任公司 | 取代的苯氧基吡啶 |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
KR20140063501A (ko) | 2010-12-22 | 2014-05-27 | 페이트 세러퓨틱스, 인코포레이티드 | 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼 |
PT2655375E (pt) | 2010-12-23 | 2015-03-02 | Sanofi Sa | Derivados de pirimidinona, sua preparação e sua utilização farmacêutica |
MX2013011329A (es) | 2011-04-01 | 2014-03-12 | Genentech Inc | Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso. |
WO2012135779A1 (en) | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt and mek inhibitor compounds, and methods of use |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
EP2714039A1 (en) * | 2011-05-23 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
CA2836364C (en) | 2011-05-25 | 2021-01-26 | Universite Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
MY170117A (en) | 2011-08-01 | 2019-07-05 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
RU2607944C2 (ru) * | 2011-08-31 | 2017-01-11 | Новартис Аг | Синергические композиции ингибиторов pi3k и мек |
EP2750672A1 (en) * | 2011-09-01 | 2014-07-09 | Novartis AG | Use of organic compound for the treatment of noonan syndrome |
EP2570127A1 (en) | 2011-09-16 | 2013-03-20 | Sanofi | Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors |
KR20200003245A (ko) | 2011-10-14 | 2020-01-08 | 어레이 바이오파마 인크. | 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물 |
CA2853806C (en) | 2011-11-02 | 2020-07-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
WO2013067162A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
EP2797957B1 (en) | 2011-11-23 | 2019-06-19 | MedImmune, LLC | Binding molecules specific for her3 and uses thereof |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
US10023862B2 (en) | 2012-01-09 | 2018-07-17 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-catenin-related diseases |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
CN103204825B (zh) | 2012-01-17 | 2015-03-04 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途 |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
AU2013235596B9 (en) * | 2012-03-20 | 2017-12-14 | Amgen Inc. | Combination therapy of a MEK inhibitor and IGF1R inhibitor |
CN104350415B (zh) | 2012-04-09 | 2018-01-16 | 思维奇材料公司 | 转换材料,及其组合物和制造方法 |
EP2856222A4 (en) | 2012-05-29 | 2016-01-27 | Switch Materials Inc | OPTICAL FILTER COMPRISING A VARIABLE TRANSMITTANCE LAYER |
BR112014029338A2 (pt) | 2012-05-31 | 2017-06-27 | Bayer Pharma AG | biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc) |
AR091876A1 (es) * | 2012-07-26 | 2015-03-04 | Novartis Ag | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas |
PL2884979T3 (pl) | 2012-08-17 | 2019-11-29 | Hoffmann La Roche | Terapie skojarzone czerniaka obejmujące podawanie kobimetynibu i wemurafinibu |
AP2015008389A0 (en) | 2012-10-02 | 2015-04-30 | Epitherapeutics Aps | Inhibitors of histone demethylases |
EA030613B1 (ru) | 2012-10-12 | 2018-08-31 | Экселиксис, Инк. | Новый способ получения соединений для применения при лечении рака |
ES2644758T3 (es) | 2012-10-16 | 2017-11-30 | Tolero Pharmaceuticals, Inc. | Moduladores de PKM2 y métodos para su uso |
PT2909182T (pt) | 2012-10-19 | 2020-03-02 | Array Biopharma Inc | Formulação contendo um inibidor de mek e a respetiva preparação |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
PL2925366T3 (pl) | 2012-11-29 | 2018-08-31 | Novartis Ag | Kombinacje farmaceutyczne |
US9867825B2 (en) | 2012-12-20 | 2018-01-16 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
CA2901747A1 (en) | 2013-02-22 | 2014-08-28 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
AP2015008676A0 (en) | 2013-02-27 | 2015-08-31 | Epitherapeutics Aps | Inhibitors of histone demethylases |
EP2963114B1 (en) | 2013-02-27 | 2018-12-12 | Daiichi Sankyo Company, Limited | Method for predicting responsiveness to compound inhibiting mapk signal transduction pathway |
AU2014236820B2 (en) | 2013-03-14 | 2018-08-02 | Sumitomo Pharma Oncology, Inc. | JAK2 and ALK2 inhibitors and methods for their use |
CN112641787A (zh) | 2013-03-21 | 2021-04-13 | 诺华股份有限公司 | 包含B-Raf抑制剂和第二抑制剂的组合疗法 |
AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
EP3083567B1 (en) | 2013-12-19 | 2018-03-07 | Idorsia Pharmaceuticals Ltd | Antibacterial 1h-indazole and 1h-indole derivatives |
CN104788365B (zh) * | 2014-01-16 | 2018-08-10 | 上海艾力斯医药科技有限公司 | 异烟酰胺衍生物、其制备方法及应用 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
AR099612A1 (es) | 2014-03-04 | 2016-08-03 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona |
EP3604499A1 (en) | 2014-03-04 | 2020-02-05 | Fate Therapeutics, Inc. | Improved reprogramming methods and cell culture platforms |
ES2770684T3 (es) | 2014-03-14 | 2020-07-02 | Novartis Ag | Moléculas de anticuerpos contra LAG-3 y usos de los mismos |
CA2943824A1 (en) | 2014-03-31 | 2015-10-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
ES2687040T3 (es) | 2014-05-16 | 2018-10-23 | Idorsia Pharmaceuticals Ltd | Derivados antibacterianos de quinazolin4(3H)ona |
US10023879B2 (en) | 2014-06-04 | 2018-07-17 | Fate Therapeutics, Inc. | Minimal volume reprogramming of mononuclear cells |
EP3169361B1 (en) | 2014-07-15 | 2019-06-19 | F.Hoffmann-La Roche Ag | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
CN107074807A (zh) | 2014-08-27 | 2017-08-18 | 吉利德科学公司 | 用于抑制组蛋白脱甲基酶的组合物和方法 |
KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
JP2017535528A (ja) | 2014-10-03 | 2017-11-30 | ノバルティス アーゲー | 組み合わせ治療 |
US20170248603A1 (en) | 2014-10-06 | 2017-08-31 | Dana-Farber Cancer Institute, Inc. | Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
MX2017004810A (es) | 2014-10-14 | 2017-10-16 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
CA2969090C (en) | 2014-12-23 | 2023-05-02 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CN105566225A (zh) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法 |
JP2016155776A (ja) * | 2015-02-24 | 2016-09-01 | 学校法人兵庫医科大学 | 抗腫瘍効果増強剤および抗腫瘍剤 |
CN107530415A (zh) | 2015-03-10 | 2018-01-02 | 艾杜罗生物科技公司 | 用于活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
MX2017012295A (es) | 2015-03-25 | 2018-01-09 | Novartis Ag | Derivados formilados n-heterociclicos como inhibidores de fgfr4. |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
AR105646A1 (es) | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
CN108348520A (zh) | 2015-08-28 | 2018-07-31 | 诺华股份有限公司 | Mdm2抑制剂和其组合 |
AR105889A1 (es) | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos |
SG10202111851YA (en) | 2015-10-16 | 2021-12-30 | Fate Therapeutics Inc | Platform for the Induction & Maintenance of Ground State Pluripotency |
MX2018005550A (es) | 2015-11-03 | 2019-07-18 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a tim-3 y sus usos. |
EP3371301A4 (en) | 2015-11-04 | 2019-06-26 | Fate Therapeutics, Inc. | METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS |
CA3003150A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Pd−1に対する抗体分子およびその使用 |
US11413309B2 (en) | 2016-01-20 | 2022-08-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
US11096964B2 (en) | 2016-01-20 | 2021-08-24 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
KR20220110859A (ko) | 2016-03-04 | 2022-08-09 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
AR108257A1 (es) | 2016-05-02 | 2018-08-01 | Mei Pharma Inc | Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas |
RU2759669C2 (ru) | 2016-06-03 | 2021-11-16 | Аррэй Байофарма Инк. | Фармацевтические комбинации |
JP2019522049A (ja) | 2016-06-20 | 2019-08-08 | ノバルティス アーゲー | トリアゾロピリジン化合物及びその使用 |
WO2017221100A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Imidazopyrimidine compounds useful for the treatment of cancer |
MX2018016331A (es) | 2016-06-20 | 2019-05-20 | Novartis Ag | Formas cristalinas de compuesto de triazolopirimidina. |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
WO2018065924A1 (en) * | 2016-10-04 | 2018-04-12 | Sun Pharmaceutical Industries Limited | Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation |
WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
CN108084078B (zh) * | 2016-11-24 | 2021-07-30 | 中山大学 | 一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法 |
WO2018106595A1 (en) | 2016-12-05 | 2018-06-14 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
EP3372624A1 (en) | 2017-03-06 | 2018-09-12 | Henkel AG & Co. KGaA | One component composition based on compounds with at least two exo-vinylene cyclic carbonate units |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
CN111646946A (zh) * | 2017-11-14 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的苯并咪唑化合物及包含该化合物的组合物 |
AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
JP6918204B2 (ja) | 2018-03-19 | 2021-08-11 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
CA3096984A1 (en) | 2018-04-05 | 2019-10-10 | Sumitomo Dainippon Pharma Oncology, Inc. | Axl kinase inhibitors and use of the same |
SG11202011633SA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Psma binding agents and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
SG11202100645XA (en) | 2018-07-25 | 2021-02-25 | Advanced Accelerator Applications Sa | Stable, concentrated radionuclide complex solutions |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
WO2020023910A1 (en) | 2018-07-26 | 2020-01-30 | Tolero Pharmaceuticals, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
HRP20230477T1 (hr) | 2018-08-17 | 2023-07-21 | Novartis Ag | Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze |
JP7358484B2 (ja) | 2018-09-25 | 2023-10-10 | アドヴァンスド・アクセラレーター・アプリケーションズ・(イタリー)・エッセエッレエッレ | 併用療法 |
CN113473978A (zh) | 2018-11-20 | 2021-10-01 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病氰基芳烃-苯胺化合物 |
CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
EP3903828A4 (en) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR |
EP3924351A4 (en) | 2019-02-12 | 2022-12-21 | Sumitomo Pharma Oncology, Inc. | FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
KR20210141621A (ko) | 2019-03-22 | 2021-11-23 | 스미토모 다이니폰 파마 온콜로지, 인크. | Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법 |
WO2020212832A1 (en) * | 2019-04-16 | 2020-10-22 | Alembic Pharmaceuticals Limited | Process of preparation of benzimidazole compounds |
MX2021012767A (es) | 2019-04-19 | 2021-11-18 | Janssen Biotech Inc | Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3. |
TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療braf相關的疾病和失調症之化合物 |
CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
AU2020355837A1 (en) | 2019-09-26 | 2022-02-24 | Novartis Ag | AZA-quinoline compounds and uses thereof |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021116901A1 (en) * | 2019-12-09 | 2021-06-17 | Biocon Limited | Forms of binimetinib and process for preparation thereof |
CA3165274A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021185291A1 (zh) * | 2020-03-17 | 2021-09-23 | 南京明德新药研发有限公司 | 蛋白降解调节剂与其使用方法 |
WO2021206167A1 (ja) | 2020-04-10 | 2021-10-14 | 大鵬薬品工業株式会社 | 3,5-二置換ベンゼンアルキニル化合物とmek阻害剤とを用いた癌治療法 |
WO2021250521A1 (en) | 2020-06-09 | 2021-12-16 | Array Biopharma Inc. | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043556A1 (en) | 2020-08-31 | 2022-03-03 | Novartis Ag | Stable radiopharmaceutical composition |
EP4225307A1 (en) | 2020-10-05 | 2023-08-16 | Pierre Fabre Medicament | Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
CN112679438A (zh) * | 2020-12-31 | 2021-04-20 | 武汉九州钰民医药科技有限公司 | 制备司美替尼的方法 |
CN112759552A (zh) * | 2020-12-31 | 2021-05-07 | 武汉九州钰民医药科技有限公司 | 司美替尼的合成方法 |
EP4281069A1 (en) * | 2021-01-21 | 2023-11-29 | NFlection Therapeutics, Inc. | Processes for preparing pyrrolopyridine-aniline compounds |
BR112023015097A2 (pt) | 2021-01-28 | 2023-10-03 | Janssen Biotech Inc | Proteínas de ligação a psma e usos das mesmas |
WO2022169780A1 (en) | 2021-02-02 | 2022-08-11 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
JP2024511373A (ja) | 2021-03-18 | 2024-03-13 | ノバルティス アーゲー | がんのためのバイオマーカーおよびその使用 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
US20220363696A1 (en) | 2021-04-13 | 2022-11-17 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
WO2022221586A1 (en) * | 2021-04-15 | 2022-10-20 | Ideaya Biosciences, Inc. | Combination therapy comprising a pkc inhibitor and a mek inhibitor |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
KR20240005899A (ko) | 2021-06-09 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 병용요법 |
CN115490640A (zh) * | 2021-06-17 | 2022-12-20 | 深圳市塔吉瑞生物医药有限公司 | 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途 |
IL309666A (en) | 2021-07-09 | 2024-02-01 | Plexium Inc | Aryl compounds and pharmaceutical preparations that modulate IKZF2 |
CN118201615A (zh) | 2021-11-04 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 喹唑啉酮化合物用于治疗癌症的新用途 |
WO2023084489A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023238000A1 (en) * | 2022-06-06 | 2023-12-14 | Glenmark Life Sciences Limited | Process for preparation of selumetinib and salts thereof |
WO2024105144A1 (en) | 2022-11-18 | 2024-05-23 | F. Hoffmann-La Roche Ag | Quinazolinone compound as braf inhibitor for the treatment of advanced solid cancer or metastases |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55501033A (zh) | 1978-11-20 | 1980-11-27 | ||
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
US5250554A (en) | 1989-10-24 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives useful as angiotensin II inhibitors |
US5218356A (en) * | 1991-05-31 | 1993-06-08 | Guenther Knapp | Wireless indoor data relay system |
US5216003A (en) | 1992-01-02 | 1993-06-01 | G. D. Searle & Co. | Diacid-containing benzimidazole compounds for treatment of neurotoxic injury |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
EP0710654A4 (en) | 1993-07-23 | 1996-08-28 | Green Cross Corp | TRIAZOLE DERIVATIVE AND ITS PHARMACEUTICAL USE |
EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
NZ270985A (en) | 1994-04-29 | 1997-06-24 | Lilly Co Eli | Substituted benzimidazole derivatives; medicaments and preparation of medicaments |
US5520187A (en) | 1994-11-25 | 1996-05-28 | General Electric Company | Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts |
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
WO1996033172A1 (en) | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
US5972980A (en) | 1995-10-05 | 1999-10-26 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
GB9600344D0 (en) | 1996-01-09 | 1996-03-13 | Lilly Co Eli | Benzimidzolyl neuropeptide y receptor antagonists |
EA199900036A1 (ru) | 1996-07-18 | 1999-06-24 | Пфайзер Инк | Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения |
JP2000501423A (ja) | 1996-08-23 | 2000-02-08 | ファイザー インク. | アリールスルホニルアミノヒドロキサム酸誘導体 |
EP0950059B1 (en) | 1997-01-06 | 2004-08-04 | Pfizer Inc. | Cyclic sulfone derivatives |
PL335027A1 (en) | 1997-02-03 | 2000-03-27 | Pfizer Prod Inc | Derivatives of arylsulphonylamino hydroxamic acid |
EP0966438A1 (en) | 1997-02-07 | 1999-12-29 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
JP3710489B2 (ja) | 1997-02-11 | 2005-10-26 | ファイザー・インク | アリールスルホニルヒドロキサム酸誘導体 |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
IL132840A (en) | 1997-07-01 | 2004-12-15 | Warner Lambert Co | Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors |
US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
ES2274572T3 (es) | 1997-07-01 | 2007-05-16 | Warner-Lambert Company Llc | Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek. |
US6821963B2 (en) * | 1997-07-01 | 2004-11-23 | Warner-Lambert Company | 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors |
US6506798B1 (en) * | 1997-07-01 | 2003-01-14 | Warner-Lambert Company | 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
US6534503B1 (en) | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
IL144103A0 (en) | 1999-01-07 | 2002-05-23 | Warner Lambert Co | Antiviral method using mek inhibitors |
EP1140062B1 (en) | 1999-01-07 | 2005-04-06 | Warner-Lambert Company LLC | Treatment of asthma with mek inhibitors |
ATE311363T1 (de) | 1999-01-13 | 2005-12-15 | Warner Lambert Co | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren |
CA2349180A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | Anthranilic acid derivatives |
DE69926800T2 (de) * | 1999-01-13 | 2006-05-18 | Warner-Lambert Company Llc | Benzoheterozyklen und ihre verwendung als mek inhibitoren |
CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
AU2482700A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
JP2000204077A (ja) | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
ES2252996T3 (es) * | 1999-01-13 | 2006-05-16 | Warner-Lambert Company Llc | Derivados de bencenosulfonamida y su uso como inhibidores de mek. |
GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
US7030119B1 (en) * | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
EP1202724B1 (en) | 1999-07-16 | 2003-10-01 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
PL352705A1 (en) | 1999-07-16 | 2003-09-08 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
WO2001005390A2 (en) * | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
HUP0202623A3 (en) | 1999-07-16 | 2003-03-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
EP1214330A1 (en) | 1999-09-21 | 2002-06-19 | LION Bioscience AG | Benzimidazole derivatives and combinatorial libraries thereof |
CA2403017A1 (en) | 2000-03-15 | 2001-09-20 | Warner-Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
US7001905B2 (en) | 2000-03-15 | 2006-02-21 | Warner-Lambert Company | Substituted diarylamines as MEK inhibitors |
JP3811775B2 (ja) | 2000-07-19 | 2006-08-23 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 4−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル |
CN1458921A (zh) | 2000-08-25 | 2003-11-26 | 沃尼尔·朗伯有限责任公司 | N-芳基邻氨基苯甲酸和它们的衍生物的制备方法 |
JP2004514718A (ja) | 2000-11-02 | 2004-05-20 | アストラゼネカ アクチボラグ | 抗癌剤としての置換キノリン類 |
US20070004713A1 (en) | 2000-12-07 | 2007-01-04 | Bernard Barlaam | Therapeutic benimidazole compounds |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
JP4544820B2 (ja) | 2001-03-09 | 2010-09-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 複素環化合物 |
US20040039208A1 (en) | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
EP1427408A4 (en) | 2001-09-17 | 2005-10-26 | Bristol Myers Squibb Co | CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM) |
AU2002348791A1 (en) | 2001-12-21 | 2003-07-09 | Warner-Lambert Company Llc | Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof |
CA2473545A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
CN1652792A (zh) * | 2002-03-13 | 2005-08-10 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
IL163995A0 (en) * | 2002-03-13 | 2005-12-18 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
DE10238002A1 (de) | 2002-08-20 | 2004-03-04 | Merck Patent Gmbh | Benzimidazolderivate |
BR0314059A (pt) | 2002-09-06 | 2005-07-05 | Janssen Pharmaceutica Nv | Compostos heterocìclicos |
US20040127395A1 (en) | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
JP4896717B2 (ja) | 2003-07-24 | 2012-03-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | N−メチル−置換ベンゾアミダゾール |
DE102005032379A1 (de) | 2005-07-08 | 2007-01-11 | Conti Temic Microelectronic Gmbh | Zugangskontrollsystem für ein Kraftfahrzeug |
TWI405756B (zh) | 2005-12-21 | 2013-08-21 | Array Biopharma Inc | 新穎硫酸氫鹽 |
US9867825B2 (en) | 2012-12-20 | 2018-01-16 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
-
2003
- 2003-03-13 IL IL16399503A patent/IL163995A0/xx unknown
- 2003-03-13 PA PA20038569301A patent/PA8569301A1/es unknown
- 2003-03-13 EP EP09011389A patent/EP2130537B1/en not_active Expired - Lifetime
- 2003-03-13 DK DK09011389.5T patent/DK2130537T3/da active
- 2003-03-13 TW TW099113360A patent/TWI350285B/zh not_active IP Right Cessation
- 2003-03-13 PT PT151771896T patent/PT3000810T/pt unknown
- 2003-03-13 ES ES10011691.2T patent/ES2549159T3/es not_active Expired - Lifetime
- 2003-03-13 PL PL401635A patent/PL233177B1/pl unknown
- 2003-03-13 SG SG200608672-2A patent/SG148857A1/en unknown
- 2003-03-13 ES ES15177189.6T patent/ES2635666T3/es not_active Expired - Lifetime
- 2003-03-13 AT AT03714148T patent/ATE449605T1/de active
- 2003-03-13 DK DK03714148.8T patent/DK1482932T3/da active
- 2003-03-13 PT PT100116912T patent/PT2275102E/pt unknown
- 2003-03-13 ES ES09011388T patent/ES2407849T3/es not_active Expired - Lifetime
- 2003-03-13 CN CN200910149291XA patent/CN101633645B/zh not_active Expired - Lifetime
- 2003-03-13 EP EP09011388.7A patent/EP2130536B1/en not_active Expired - Lifetime
- 2003-03-13 SG SG2013013339A patent/SG2013013339A/en unknown
- 2003-03-13 PL PL401636A patent/PL233493B1/pl unknown
- 2003-03-13 SI SI200332221T patent/SI2130537T1/sl unknown
- 2003-03-13 PL PL377628A patent/PL230179B1/pl unknown
- 2003-03-13 ES ES03714148T patent/ES2335276T3/es not_active Expired - Lifetime
- 2003-03-13 PL PL401638A patent/PL401638A1/pl unknown
- 2003-03-13 KR KR1020107007539A patent/KR100984573B1/ko active IP Right Grant
- 2003-03-13 DK DK15177189.6T patent/DK3000810T3/en active
- 2003-03-13 AU AU2003218157A patent/AU2003218157C1/en active Active
- 2003-03-13 EP EP15177189.6A patent/EP3000810B1/en not_active Revoked
- 2003-03-13 WO PCT/US2003/007864 patent/WO2003077914A1/en active Application Filing
- 2003-03-13 CA CA002478374A patent/CA2478374C/en not_active Expired - Lifetime
- 2003-03-13 KR KR1020047014182A patent/KR100984595B1/ko active IP Right Grant
- 2003-03-13 PT PT90113895T patent/PT2130537E/pt unknown
- 2003-03-13 TW TW092105718A patent/TWI338685B/zh not_active IP Right Cessation
- 2003-03-13 HU HUE10011691A patent/HUE025767T2/en unknown
- 2003-03-13 NZ NZ535158A patent/NZ535158A/en not_active IP Right Cessation
- 2003-03-13 ZA ZA200407220A patent/ZA200407220B/xx unknown
- 2003-03-13 US US10/387,879 patent/US20030232869A1/en not_active Abandoned
- 2003-03-13 EP EP03714148A patent/EP1482932B1/en not_active Expired - Lifetime
- 2003-03-13 TW TW099113379A patent/TWI343377B/zh not_active IP Right Cessation
- 2003-03-13 PT PT03714148T patent/PT1482932E/pt unknown
- 2003-03-13 KR KR1020107007537A patent/KR100984613B1/ko active Protection Beyond IP Right Term
- 2003-03-13 AR ARP030100887A patent/AR038971A1/es active IP Right Grant
- 2003-03-13 JP JP2003575967A patent/JP4093966B2/ja not_active Expired - Lifetime
- 2003-03-13 SI SI200332449T patent/SI2275102T1/sl unknown
- 2003-03-13 MX MXPA04008893A patent/MXPA04008893A/es active IP Right Grant
- 2003-03-13 SI SI200331731T patent/SI1482932T1/sl unknown
- 2003-03-13 ES ES09011389T patent/ES2394347T3/es not_active Expired - Lifetime
- 2003-03-13 CN CN2009101492905A patent/CN101633644B/zh not_active Expired - Lifetime
- 2003-03-13 SG SG2011042850A patent/SG194238A1/en unknown
- 2003-03-13 DE DE60330227T patent/DE60330227D1/de not_active Expired - Lifetime
- 2003-03-13 SI SI200332546T patent/SI3000810T1/sl unknown
- 2003-03-13 PL PL401637A patent/PL401637A1/pl unknown
- 2003-03-13 CN CNB038107546A patent/CN100519539C/zh not_active Expired - Lifetime
- 2003-03-13 DK DK10011691.2T patent/DK2275102T3/en active
- 2003-03-13 UA UA20040907722A patent/UA77765C2/uk unknown
- 2003-03-13 DO DO2003000613A patent/DOP2003000613A/es unknown
- 2003-03-13 EP EP10011691.2A patent/EP2275102B1/en not_active Expired - Lifetime
- 2003-03-13 CN CN2008101903429A patent/CN101486682B/zh not_active Expired - Lifetime
- 2003-12-12 BR BR122018007328A patent/BR122018007328B8/pt active IP Right Grant
-
2004
- 2004-09-09 IS IS7442A patent/IS2748B/is unknown
- 2004-09-09 IL IL163995A patent/IL163995A/en active IP Right Grant
-
2005
- 2005-02-18 US US11/061,336 patent/US7425637B2/en not_active Expired - Lifetime
- 2005-04-26 HK HK05103569.0A patent/HK1070823A1/xx not_active IP Right Cessation
-
2007
- 2007-10-09 JP JP2007263512A patent/JP2008019277A/ja active Pending
-
2008
- 2008-01-29 JP JP2008017547A patent/JP5102642B2/ja not_active Expired - Lifetime
- 2008-03-18 US US12/050,827 patent/US7777050B2/en not_active Expired - Lifetime
- 2008-03-18 US US12/050,847 patent/US7576114B2/en not_active Expired - Lifetime
-
2009
- 2009-10-07 AU AU2009222613A patent/AU2009222613B2/en active Active
-
2010
- 2010-01-13 CY CY20101100037T patent/CY1109727T1/el unknown
- 2010-03-10 IL IL204420A patent/IL204420A/en active Protection Beyond IP Right Term
- 2010-03-10 IL IL204419A patent/IL204419A/en active IP Right Grant
- 2010-06-09 HK HK10105717.9A patent/HK1141976A1/xx not_active IP Right Cessation
- 2010-06-28 US US12/824,521 patent/US8193229B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,559 patent/US8178693B2/en not_active Expired - Fee Related
- 2010-06-28 US US12/824,497 patent/US7973170B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,477 patent/US8003805B2/en not_active Expired - Lifetime
- 2010-06-28 US US12/824,547 patent/US8193230B2/en not_active Expired - Lifetime
- 2010-06-29 US US12/826,158 patent/US8193231B2/en not_active Expired - Lifetime
-
2011
- 2011-04-20 DO DO2011000110A patent/DOP2011000110A/es unknown
- 2011-04-20 DO DO2011000109A patent/DOP2011000109A/es unknown
- 2011-06-16 IS IS8960A patent/IS2998B/is unknown
- 2011-06-16 IS IS8961A patent/IS2999B/is unknown
- 2011-06-16 IS IS8959A patent/IS2990B/is unknown
- 2011-07-13 HK HK11107302.5A patent/HK1153139A1/zh not_active IP Right Cessation
-
2012
- 2012-05-03 US US13/463,487 patent/US8513293B2/en not_active Expired - Lifetime
- 2012-08-24 JP JP2012184708A patent/JP5498546B2/ja not_active Expired - Lifetime
- 2012-08-29 CL CL2012002380A patent/CL2012002380A1/es unknown
- 2012-08-29 CL CL2012002381A patent/CL2012002381A1/es unknown
-
2013
- 2013-01-28 DO DO2013000023A patent/DOP2013000023A/es unknown
- 2013-02-25 AR ARP130100567A patent/AR090143A2/es unknown
- 2013-02-25 AR ARP130100568A patent/AR090144A2/es unknown
-
2017
- 2017-07-27 CY CY20171100805T patent/CY1119136T1/el unknown
-
2019
- 2019-02-12 LU LU00100C patent/LUC00100I2/fr unknown
- 2019-03-01 HU HUS1900011C patent/HUS1900011I1/hu unknown
- 2019-03-07 LT LTPA2019007C patent/LTC1482932I2/lt unknown
- 2019-03-13 BE BE2019C510C patent/BE2019C510I2/fr unknown
- 2019-03-15 NL NL300974C patent/NL300974I2/nl unknown
- 2019-03-18 CY CY2019012C patent/CY2019012I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS1900011I1 (hu) | N3 alkilált benzimidazol-származékok, mint MEK inhibitorok | |
IL163996A0 (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
IL173935A0 (en) | N3 alkylated benzimidazole derivatives as mek inhibitors | |
IL165810A0 (en) | Novel benzimidazole derivatives | |
HK1071360A1 (en) | 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors | |
ATE386518T1 (de) | Benzimidazolderivate | |
IS7509A (is) | Þíoxantínafleiður sem mergperoxídasatálmar | |
SI1569912T1 (sl) | Derivati 2-(2-hidroksibifenil-3-il)-1h-benzoimidazol-5-karboksamidina kot inhibitorji faktorja viia | |
AU2003232362A8 (en) | 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors | |
IL169094A0 (en) | 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20230312 |